Taysha Gene Therapies, Inc. Q1 FY2026 earnings call

CEO Sean Nolan provided updates on regulatory activities like breakthrough therapy meeting with FDA, BLA-enabling PPQ campaign initiation; clinical progress with dosing in Reveal Pivotal trial and ongoing enrollment in INSPIRE trial; R&D head Dr. Sukumar Nagandran discussed preclinical data validating TASHA-102's construct and intrathecal route; CFO Cameron Alaa gave financial update with R&D and G&A expenses increase; also mentioned building commercial infrastructure.

Details about product segment financial performance not explicitly stated with absolute terms and revenue contribution % as no specific product line financials are detailed in the provided transcript but focus on TASHA-102 development

Management expects to complete BLA-enabling PPQ campaign by Q4 2026, confident CMC activities on track for BLA submission in line with Pivotal Data Readout; anticipate reporting longer-term data from Reveal Phase 1-2 Part A trials this quarter; see potential for expedited BLA submission based on six-month interim analysis.

Various risks including actual results differing from forward-looking statements, risks related to clinical trial outcomes, regulatory approval process uncertainties, and commercialization challenges as detailed in SEC filings.

Organized as pairs like Q: Kristen Kluska from Cantor asks about data at ASGCT, A: Sean and Sukhu respond on construct and transduction efficiency; Q: Selveen Richter from Goldman Sachs asks about BLA submission pathway, A: Sean answers on FDA dialogue and scenarios; etc. as per the provided Q&A exchanges